New drug combo tested for Tough-to-Treat lung cancer
Disease control
Recruiting now
This early-stage study aims to find a safe and effective dose when combining two drugs (osimertinib and carotuximab) for people with advanced lung cancer that has a specific genetic change (EGFR mutation). Researchers will enroll 60 adults whose cancer has progressed despite prev…
Phase: PHASE1 • Sponsor: Karen Reckamp, MD, MS • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC